Systemic sclerosis & Raynaud's
Association between anti-SSSCA1 antibodies and cancer in systemic sclerosis
Authors' conclusion
These data suggest anti-SSSCA1 antibody status may be of utility as a cancer biomarker in SSc. Anti-SSSCA1-positive patients with SSc may be more likely to have severe Raynaud's and cardiac involvement.
Study context
- Population
- Patients with SSc randomly selected from the Johns Hopkins Scleroderma Center Research Registry
- Participants
- 414 patients
- Comparison
- SSc with cancer vs SSc without cancer
- Cancern = 209
- No cancern = 205reference
- Outcome
- Association between anti-SSSCA1 antibodies and cancer
Methodological detailslogistic regression, randomly selected from registry
- Logistic regression
- Randomly selected from registry
Main finding
As reported in the abstract
Anti-SSSCA1 antibody positivity
P = 0.018
- Anti-SSSCA1 positive vs negative: adjusted risk of cancer, OR
- 2.46 (95% CI 1.06, 5.70)
Observational data: associations, not effects.
Further findings
Anti-SSSCA1 antibody prevalence, all patients
- Anti-SSSCA1 antibody positive among 414 patients: 31 (7%)
Clinical phenotype of anti-SSSCA1-positive vs negative patients
- More likely severe RP, lower minimum ejection fraction, trend towards more severe heart involvement, lower baseline DLCO % predicted
Cancer–SSc interval among patients with cancer
- Trend towards longer cancer-SSc interval in anti-SSSCA1-positive vs negative patients
Original publication
Association between anti-SSSCA1 antibodies and cancer in systemic sclerosis. Rheumatology (Oxford). Published 15 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →